The short answer
Avoid adding willow bark to celecoxib without medical advice. This follows an explicit willow bark precaution for NSAIDs; taking the products a few hours apart has not been shown to resolve the concern.
What this answer covers
Oral willow bark preparations covered by the final EMA Salix cortex monograph, including S. purpurea, S. daphnoides and S. fragilis. The broad Willow Bark identity does not establish a product species, preparation or salicin dose.
- Supplement or preparation
- Willow Bark
- Medication ingredient
- celecoxib
Why the combination deserves review
The final EMA willow bark monograph advises against concurrent use with salicylates or other NSAIDs without medical advice. Celecoxib is an NSAID, so this is relevant guidance even though the monograph does not report a clinical trial of this exact pair.
Willow products are not interchangeable
The monograph covers specified Salix species and bark preparations. A label that says willow bark alone does not tell you which species, extraction method or salicin amount it contains. Show the complete label to your pharmacist; willow bark cannot simply be assigned an aspirin-equivalent dose.
Do not rely on taking them hours apart
Discuss another pain-relief plan before adding willow bark. The precaution concerns concurrent use and is not a proven timing instruction. The inspected sources give no number of hours that makes the combination safe. Celecoxib labeling also cautions against combining NSAIDs or salicylates because of gastrointestinal toxicity.
Watch for gastrointestinal bleeding
Celecoxib can cause serious stomach or intestinal bleeding even without early warning. Stop celecoxib and seek prompt medical help for blood in vomit, black or bloody stools, or faintness with suspected bleeding. A history of ulcers, older age and other bleeding-affecting medicines make a careful review especially important.
Evidence and practical considerations
Timing & monitoring
Do not add a willow bark medicinal preparation to celecoxib without medical advice; the final EMA monograph advises against unsupervised concurrent NSAID use.
- Exact scope
- Oral willow bark preparations covered by the final EMA Salix cortex monograph, including S. purpurea, S. daphnoides and S. fragilis. The broad Willow Bark identity does not establish a product species, preparation or salicin dose. with Celecoxib, RxCUI 140587 IN, oral treatment.
- Medication form and route
- Oral
What remains uncertain
- An explicit regulatory NSAID precaution supports clinician review, not a measured celecoxib-willow interaction, dose equivalence to aspirin, a bleeding rate or a safe spacing interval.
Factors that may matter: Exact product and dose; Kidney function; Other medicines; Prior gastrointestinal bleeding or ulcers.
Read the supporting source summaries
Source 1: Regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral celecoxib.
Celecoxib can cause serious gastrointestinal bleeding. The label also warns of renal toxicity and hyperkalemia. Healthy-volunteer testing found no reduction of platelet aggregation or increase in bleeding time at the tested celecoxib regimens.
How this applies: Exact celecoxib identity, baseline risks and clinical counseling; no direct botanical co-use outcome.
Baseline adverse effects do not prove an added botanical interaction. NSAID wording must not be converted into an aspirin-like platelet effect for celecoxib.
Source 2: Final regulatory herbal monograph
ema.europa.eu · Source check Sep 10, 2026
Population: Users of the specified willow bark medicinal preparations.
Both columns advise against concurrent salicylates or other NSAIDs without medical advice.
How this applies: The explicit NSAID precaution includes celecoxib as an NSAID, while retaining species and preparation limits. No hours-apart prevention rule is established.
Regulatory precaution, not an exact celecoxib clinical trial. The broad Willow Bark node does not identify the species, extract or salicin exposure of a product. A coumarin warning in section 4.5 does not make celecoxib an anticoagulant.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources checked and article drafted. | |
| Research summary published |
Article revision: 2c3263751365edf2
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.